RPI-MN is under clinical development by ReceptoPharm and currently in Phase I for Human Immunodeficiency Virus (HIV) Infections (AIDS). According to GlobalData, Phase I drugs for Human Immunodeficiency Virus (HIV) Infections (AIDS) have a 68% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how RPI-MN’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
RPI-MN (modified cobratoxin) is under development for the treatment of human immunodeficiency virus infections. The drug candidate is administered as an injectable and orally. RPI-MN is a modified cobra venom for viral diseases. It was also under development for herpes simplex keratitis, rheumatoid arthritis, and amyotrophic lateral sclerosis.
ReceptoPharm, formerly Receptogen, a subsidiary of Nutra Pharma Corp, is a biopharmaceutical drug discovery company that discovers and develops therapeutic protein products. The company’s products are used to prevent and treat various viral, neurological and autoimmune diseases. Its products are used in the treatment of adrenomyeloneuropathy, rheumatoid arthritis, pain, multiple sclerosis, myasthenia gravis and human immunodeficiency virus. ReceptoPharm offers contract services to start-up and small biotechnology companies. The company’s contract services include contract manufacturing services, drug development services, pre-production studies, US and EU regulatory support, and quality systems, among others. ReceptoPharm is headquartered in Plantation, Florida, the US.
For a complete picture of RPI-MN’s drug-specific PTSR and LoA scores, buy the report here.